Gliptus Plus 50/500 Mg

Gliptus Plus 50/500 Mg

Description:

Gliptus Plus 50/500 mg is an oral anti-diabetic prescription medicine used for the management of type 2 diabetes mellitus in adults. It combines vildagliptin, a DPP-4 inhibitor, with metformin hydrochloride, a biguanide, in a single tablet to help control blood glucose levels when diet and exercise alone, or metformin alone, are not sufficient. By targeting both insulin secretion and hepatic glucose production, Gliptus Plus 50/500 mg supports effective and sustained glycemic control and helps reduce the risk of diabetes-related complications as part of a comprehensive diabetes care plan.

Indications:

• Type 2 diabetes mellitus in adults, especially in patients insufficiently controlled on metformin alone.
• Improvement of glycemic control (fasting and postprandial blood glucose levels) in type 2 diabetic patients.
• May be used as part of combination therapy with other anti-diabetic agents as prescribed by the physician.
• Helps manage symptoms related to high blood sugar such as excessive thirst, frequent urination, and fatigue when used alongside diet and exercise.

Active Ingredients / Key Components:

• Vildagliptin – 50 mg per tablet (dipeptidyl peptidase-4 (DPP-4) inhibitor).
• Metformin hydrochloride – 500 mg per tablet (biguanide oral anti-diabetic).
• Other excipients: The full list of inactive ingredients (excipients, coating agents, stabilizers) is not available in the provided information. Please refer to the official package leaflet for complete details.

Dosage & Administration / How to Use:

• Use only as prescribed by a physician experienced in the management of diabetes.
• Typical adult dose: Often 1 tablet twice daily (morning and evening) with meals; however, the exact dose, frequency, and duration must be individualized by the treating doctor based on blood glucose levels and previous therapy.
• Tablets should be swallowed whole with a glass of water and taken with food to reduce gastrointestinal side effects associated with metformin.
• Do not crush, chew, or break the tablets unless your doctor or pharmacist specifically advises otherwise.
• If a dose is missed, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose to make up for a missed dose.
• Regular monitoring of blood glucose, HbA1c, kidney function, and liver function is recommended during treatment.
• Therapy should be combined with an appropriate diet plan, weight control, and regular physical activity for optimal diabetes management.

Clinical Benefits:

• Provides dual mechanism of action: vildagliptin enhances glucose-dependent insulin secretion and reduces glucagon levels, while metformin decreases hepatic glucose production and improves peripheral insulin sensitivity.
• Helps achieve better glycemic control in type 2 diabetes compared to metformin monotherapy in patients who are inadequately controlled.
• Supports reduction of fasting and postprandial blood glucose levels, contributing to improved HbA1c over time.
• Metformin component may help improve lipid profile in type 2 diabetic patients, supporting cardiovascular risk management as part of overall care.
• Convenient fixed-dose combination (50/500 mg) can simplify treatment regimens and may improve adherence compared to taking separate tablets.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to vildagliptin, metformin, or any of the tablet components.
• Contraindicated in patients with severe renal impairment or significant renal dysfunction, due to increased risk of lactic acidosis associated with metformin.
• Contraindicated in acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
• Use with caution in patients with liver impairment; vildagliptin has been associated with rare cases of hepatic dysfunction. Liver function tests may be required periodically.
• Risk of lactic acidosis: Metformin can rarely cause lactic acidosis, a serious metabolic complication. This risk is increased in conditions such as renal impairment, dehydration, severe infection, heart failure, respiratory failure, or excessive alcohol intake.
• Discontinue temporarily before radiologic studies with iodinated contrast agents or major surgery, as advised by the physician.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Use in pregnancy and lactation should only occur if clearly needed and under medical supervision.
• Use with caution in elderly patients and those with cardiovascular or respiratory disease.
• Monitor blood glucose regularly to avoid hypoglycemia, especially if used in combination with other anti-diabetic drugs that can cause low blood sugar.
• Not intended to diagnose, treat, cure, or prevent any disease without medical supervision.
• Keep out of reach of children.

Side Effects:

• Common side effects (usually mild and transient): nausea, vomiting, diarrhea, abdominal discomfort, loss of appetite, and metallic taste (mainly due to metformin); headache, dizziness, and mild upper respiratory symptoms (sometimes associated with vildagliptin).
• Less common side effects: weight loss, mild skin reactions, peripheral edema, or joint pain.
• Serious but rare side effects: lactic acidosis (symptoms include rapid breathing, abdominal pain, severe weakness, muscle cramps, and drowsiness), severe liver dysfunction (jaundice, dark urine, persistent nausea), or severe allergic reactions (rash, swelling, difficulty breathing).
• Hypoglycemia is uncommon with vildagliptin/metformin alone but may occur when combined with sulfonylureas, insulin, or other hypoglycemic agents.
• Stop using the medicine and seek immediate medical attention if you experience symptoms of lactic acidosis, severe abdominal pain, unexplained fatigue, yellowing of skin/eyes, or signs of a serious allergic reaction.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children. Do not use after the expiry date printed on the pack. Store at or below the temperature specified on the package insert (exact storage temperature is not available in the provided information; refer to the official leaflet).

Specifications:

• Form: Film-coated tablets for oral use.
• Strength per tablet: vildagliptin 50 mg + metformin hydrochloride 500 mg.
• Pack size: 30 tablets per pack (30 tabs) – quantity suitable for typical short-term supply depending on prescribed dose.
• Intended use: Prescription anti-diabetic medicine for adults with type 2 diabetes mellitus.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.